KMT2A and acute myeloid leukemia: A phase I clinical study evaluated Iadademstat in relapsed or refractory AML patients: the dose-escalation section of the study carried out in 27 patients showed that the recommended dose of Iadademstat for an extension cohort was 140 μg/m2 administered as a single agent from day 1 to 5 of 28-day cycles; in the extension cohort, 14 additional patients were treated, including 5 patients with MLL/KMT2A-rearranged AMLs [81].